Elanco Animal Health Incorporated (NYSE:ELAN) Receives $28.55 Average Price Target from Analysts

Posted by Francis Steltz on Jun 26th, 2026

Shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $28.5455.

A number of equities research analysts recently weighed in on the company. Citigroup lifted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. TD Cowen boosted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th.

Read Our Latest Stock Report on ELAN

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company’s stock.

Institutional Trading of Elanco Animal Health

A number of hedge funds have recently modified their holdings of ELAN. NewEdge Advisors LLC grew its holdings in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the period. Huntington National Bank increased its position in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares in the last quarter. Root Financial Partners LLC raised its stake in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares during the period. Uniplan Investment Counsel Inc. acquired a new stake in Elanco Animal Health during the 4th quarter worth $41,000. Finally, Torren Management LLC bought a new position in Elanco Animal Health during the fourth quarter worth about $46,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Up 1.7%

ELAN opened at $24.36 on Friday. The business has a 50 day moving average of $23.02 and a 200-day moving average of $23.55. The stock has a market capitalization of $12.17 billion, a price-to-earnings ratio of -48.72, a P/E/G ratio of 1.57 and a beta of 1.69. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 1-year low of $13.39 and a 1-year high of $27.72.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the previous year, the firm posted $0.37 earnings per share. Elanco Animal Health’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health will post 1.11 earnings per share for the current year.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.